

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2020

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: **001-34487**

**LIGHTBRIDGE
CORPORATION**

(Exact name of registrant as specified in its charter)

Nevada
*(State or other jurisdiction
of incorporation or organization)*

91-1975651
(I.R.S. Empl. Ident. No.)

**11710 Plaza America Drive, Suite 2000
Reston, VA 20190**
(Address of principal executive offices, Zip Code)

(571) 730-1200
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class:</u>	<u>Trading Symbol(s):</u>	<u>Name of Each Exchange on Which Registered:</u>
Common Stock, \$0.001 par value	LTBR	The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	<input type="checkbox"/>	Accelerated Filer	<input type="checkbox"/>
Non-accelerated Filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares outstanding of the issuer's common stock, as of November 5, 2020 is as follows:

<u>Class of Securities</u>	<u>Shares Outstanding</u>
Common Stock, \$0.001 par value	5,631,561

LIGHTBRIDGE CORPORATION
Form 10-Q
SEPTEMBER 30, 2020

Page

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)	
	Unaudited Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019	3
	Unaudited Condensed Consolidated Statements of Operations for The Three Months and Nine Months Ended September 30, 2020 and 2019	4
	Unaudited Condensed Consolidated Statements of Cash Flows for The Nine Months Ended September 30, 2020 and 2019	5
	Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity for The Nine Months Ended September 30, 2019 and For The Nine Months Ended September 30, 2020	6
	Notes to Condensed Consolidated Financial Statements (unaudited)	8
	Forward-Looking Statements	25
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	37
Item 4.	Controls and Procedures	37

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	38
Item 1A.	Risk Factors	38
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	38
Item 3.	Defaults Upon Senior Securities	38
Item 4.	Mine Safety Disclosures	39
Item 5.	Other Information	39
Item 6.	Exhibits	39
SIGNATURES		40

PART I—FINANCIAL INFORMATION

Lightbridge Corporation
Unaudited Condensed Consolidated Balance Sheets

	<u>September 30,</u> <u>2020</u>	<u>December 31,</u> <u>2019</u>
ASSETS		
Current Assets		
Cash and cash equivalents	\$ 17,410,899	\$ 17,958,989
Other receivable from joint venture	—	400,000
Prepaid expenses and other current assets	<u>164,652</u>	<u>47,371</u>
Total Current Assets	17,575,551	18,406,360
Other Assets		
Patent costs	1,825,326	1,798,484
Total Assets	<u>\$ 19,400,877</u>	<u>\$ 20,204,844</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities		
Accounts payable and accrued liabilities	<u>\$ 1,815,791</u>	<u>\$ 350,299</u>
Total Current Liabilities	1,815,791	350,299
Commitments and contingencies – (Note 5)		
Stockholders' Equity		
Preferred stock, \$0.001 par value, 10,000,000 authorized shares:		
Convertible Series A preferred shares, 712,126 and 757,770 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively (liquidation preference \$2,612,802 and \$2,636,764 at September 30, 2020 and December 31, 2019, respectively)	712	757
Convertible Series B preferred shares, 2,666,667 issued and outstanding at September 30, 2020 and December 31, 2019, (liquidation preference \$4,813,284 and \$4,569,180 at September 30, 2020 and December 31, 2019, respectively)	2,667	2,667
Common stock, \$0.001 par value, 8,333,333 authorized, 4,416,961 and 3,252,371 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	4,417	3,252
Additional paid-in capital	139,121,290	133,932,615
Accumulated deficit	<u>(121,544,000)</u>	<u>(114,084,746)</u>
Total Stockholders' Equity	<u>17,585,086</u>	<u>19,854,545</u>
Total Liabilities and Stockholders' Equity	<u>\$ 19,400,877</u>	<u>\$ 20,204,844</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Lightbridge Corporation
Unaudited Condensed Consolidated Statements of Operations

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2020	2019	2020	2019
Revenue	\$ —	\$ —	\$ —	\$ —
Operating Expenses				
General and administrative	2,835,471	1,463,568	6,800,892	4,051,484
Research and development	261,898	751,473	767,498	2,218,826
Total Operating Expenses	<u>3,097,369</u>	<u>2,215,041</u>	<u>7,568,390</u>	<u>6,270,310</u>
Other Operating Income and (Loss)				
Grant income	29,662	—	29,662	—
Other income from joint venture	—	247,568	—	908,224
Equity in loss from joint venture	—	(555,113)	—	(3,812,463)
Total Other Operating Income and (Loss)	<u>29,662</u>	<u>(307,545)</u>	<u>29,662</u>	<u>(2,904,239)</u>
Operating Loss	<u>(3,067,707)</u>	<u>(2,522,586)</u>	<u>(7,538,728)</u>	<u>(9,174,549)</u>
Other Income				
Interest income	4,645	81,172	79,474	315,691
Total Other Income	<u>4,645</u>	<u>81,172</u>	<u>79,474</u>	<u>315,691</u>
Loss before income taxes	<u>(3,063,062)</u>	<u>(2,441,414)</u>	<u>(7,459,254)</u>	<u>(8,858,858)</u>
Income taxes	—	—	—	—
Net Loss	<u>\$ (3,063,062)</u>	<u>\$ (2,441,414)</u>	<u>\$ (7,459,254)</u>	<u>\$ (8,858,858)</u>
Accumulated preferred stock dividend	(128,937)	(123,455)	(383,086)	(365,973)
Deemed additional dividend on preferred stock dividend due the beneficial conversion feature	(55,940)	(53,047)	(165,551)	(156,232)
Net loss attributable to common stockholders	<u>\$ (3,247,939)</u>	<u>\$ (2,617,916)</u>	<u>\$ (8,007,891)</u>	<u>\$ (9,381,063)</u>
Net Loss Per Common Share				
Basic and Diluted	<u>\$ (0.80)</u>	<u>\$ (0.81)</u>	<u>\$ (2.22)</u>	<u>\$ (3.07)</u>
Weighted Average Number of Common Shares Outstanding	<u>4,053,644</u>	<u>3,222,226</u>	<u>3,613,349</u>	<u>3,058,797</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Lightbridge Corporation
Unaudited Condensed Consolidated Statements of Cash Flows

	Nine Months Ended September 30,	
	2020	2019
Operating Activities		
Net Loss	\$ (7,459,254)	\$ (8,858,858)
Adjustments to reconcile net loss from operations to net cash used in operating activities		
Common stock issued for services and stock-based compensation	25,110	591,663
Patent write-off	111,850	—
Equity in loss from joint venture	—	3,812,463
Changes in operating working capital items:		
Other receivable from joint venture	400,000	(540,155)
Prepaid expenses and other current assets	(117,281)	(60,288)
Accounts payable and accrued liabilities	1,465,492	937,836
Net Cash Used in Operating Activities	(5,574,083)	(4,117,339)
Investing Activities		
Investment in joint venture	—	(3,540,000)
Patent costs	(138,692)	(148,432)
Net Cash Used in Investing Activities	(138,692)	(3,688,432)
Financing Activities		
Net proceeds from issuances of common stock and exercise of stock options	5,164,685	3,750,454
Net Cash Provided by Financing Activities	5,164,685	3,750,454
Net Decrease in Cash and Cash Equivalents	(548,090)	(4,055,317)
Cash and Cash Equivalents, Beginning of Period	17,958,989	24,637,295
Cash and Cash Equivalents, End of Period	\$ 17,410,899	20,581,978
Supplemental Disclosure of Cash Flow Information		
Cash paid during the period		
Interest paid	\$ —	\$ —
Income taxes paid	\$ —	\$ —
Non-Cash Financing Activities		
Accumulated preferred stock dividend	\$ 548,637	\$ 522,205
Conversion of Series A convertible preferred stock to common stock and payment of paid-in-kind dividends to Series A preferred stockholder	\$ 38,071	\$ 91,635
Common stock issued for services	\$ 17,000	\$ —

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Lightbridge Corporation
Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity
For the Three and Nine Months Ended September 30, 2019 and September 30, 2020

	Series A Preferred Stock		Series B Preferred Stock		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Equity
	Shares	Amount	Shares	Amount	Shares	Amount			
Balance – January 1, 2019	813,624	\$ 813	2,666,667	\$ 2,667	2,738,508	\$ 2,738	\$ 129,359,799	\$(103,497,622)	\$25,868,395
Shares issued - registered offerings – net of offering costs	—	—	—	—	273,936	274	1,986,211	—	1,986,485
Stock-based compensation	—	—	—	—	—	—	335,013	—	335,013
Net loss for the three months ended March 31, 2019	—	—	—	—	—	—	—	(3,110,527)	(3,110,527)
Balance – March 31, 2019	813,624	\$ 813	2,666,667	\$ 2,667	3,012,444	\$ 3,012	\$ 131,681,023	\$(106,608,149)	\$25,079,366
Conversion of 27,747 Preferred Shares to 2,782 common shares	(27,747)	(28)	—	—	2,782	3	25	—	—
Shares issued - registered offerings – net of offering costs	—	—	—	—	118,600	119	929,795	—	929,914
Stock-based compensation	—	—	—	—	—	—	237,272	—	237,272
Net loss for the three months ended June 30, 2019	—	—	—	—	—	—	—	(3,306,917)	(3,306,917)
Balance – June 30, 2019	785,877	\$ 785	2,666,667	\$ 2,667	3,133,826	\$ 3,134	\$ 132,848,116	\$(109,915,066)	\$22,939,635
Shares issued - registered offerings – net of offering costs	—	—	—	—	115,527	115	833,940	—	834,055
Stock-based compensation	—	—	—	—	—	—	19,378	—	19,378
Net loss for the three months ended September 30, 2019	—	—	—	—	—	—	—	(2,441,414)	(2,441,414)
Balance – September 30, 2019	<u>785,877</u>	<u>\$ 785</u>	<u>2,666,667</u>	<u>\$ 2,667</u>	<u>3,249,353</u>	<u>\$ 3,249</u>	<u>\$ 133,701,433</u>	<u>\$(112,356,480)</u>	<u>\$21,351,654</u>

[Table of Contents](#)

	Series A Preferred Stock		Series B Preferred Stock		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Equity
	Shares	Amount	Shares	Amount	Shares	Amount			
Balance – January 1, 2020	757,770	\$ 757	2,666,667	\$ 2,667	3,252,371	\$ 3,252	\$ 133,932,615	\$(114,084,746)	\$ 19,854,545
Conversion of 11,875 preferred shares to 1,255 common shares	(11,875)	(12)	—	—	1,255	1	11	—	—
Shares issued - registered offerings – net of offering costs	—	—	—	—	110,053	111	399,564	—	399,675
Stock-based compensation	—	—	—	—	—	—	6,085	—	6,085
Net loss for the three months ended March 31, 2020	—	—	—	—	—	—	—	(2,264,086)	(2,264,086)
Balance – March 31, 2020	745,895	\$ 745	2,666,667	\$ 2,667	3,363,679	\$ 3,364	\$ 134,338,275	\$(116,348,832)	\$ 17,996,219
Conversion of 17,080 preferred shares to 1,847 common shares	(17,080)	(17)	—	—	1,847	2	15	—	—
Shares issued - registered offerings – net of offering costs	—	—	—	—	437,341	437	2,277,885	—	2,278,322
Exercise of 6,548 options at \$3.82 each	—	—	—	—	6,548	6	25,007	—	25,013
Stock-based compensation	—	—	—	—	—	—	6,085	—	6,085
Net loss for the three months ended June 30, 2020	—	—	—	—	—	—	—	(2,132,106)	(2,132,106)
Balance – June 30, 2020	728,815	\$ 728	2,666,667	\$ 2,667	3,809,415	\$ 3,809	\$ 136,647,267	\$(118,480,938)	\$ 18,173,533
Conversion of 16,689 preferred shares to 1,846 common shares	(16,689)	(16)	—	—	1,846	2	14	—	—
Shares issued - registered offerings – net of offering costs	—	—	—	—	601,700	602	2,461,073	—	2,461,675
Common stock issued to consultant for services	—	—	—	—	4,000	4	16,996	—	17,000
Reverse of stock-based compensation for forfeited stock options	—	—	—	—	—	—	(4,060)	—	(4,060)
Net loss for the three months ended September 30, 2020	—	—	—	—	—	—	—	(3,063,062)	(3,063,062)
Balance – September 30, 2020	712,126	\$ 712	2,666,667	\$ 2,667	4,416,961	\$ 4,417	\$ 139,121,290	\$(121,544,000)	\$ 17,585,086

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

LIGHTBRIDGE CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 1. Basis of Presentation, Summary of Significant Accounting Policies, and Nature of Operations

Basis of presentation

The accompanying unaudited condensed consolidated financial statements of Lightbridge Corporation and its subsidiaries have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America, including a summary of the Company's significant accounting policies, have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive consolidated financial statements and should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2019, included in our Annual Report on Form 10-K for the year ended December 31, 2019.

In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim period presented are not necessarily indicative of the results that might be expected for the entire fiscal year. When used in these notes, the terms "Lightbridge", "Company," "we," "us" or "our" mean Lightbridge Corporation and all entities included in our condensed consolidated financial statements.

The Company was formed on October 6, 2006, when Thorium Power, Ltd., which was incorporated in the state of Nevada on February 2, 1999, merged with Thorium Power, Inc. ("TPI"), which was incorporated in the state of Delaware on January 8, 1992. On September 29, 2009, the Company changed its name from Thorium Power, Ltd. to Lightbridge Corporation and began its focus on developing and commercializing metallic nuclear fuels. The Company is a nuclear fuel technology company developing and commercializing next generation nuclear fuel technology.

Going Concern, Liquidity and Management's Plan

The Company currently believes the combination of cash on hand at September 30, 2020 and management's reduction in budgeted operating expenses for 2020, will be sufficient to allow the Company to meet its obligations, as they become due in the ordinary course of business, for at least 12 months following the date of this filing. While the Company's cash at September 30, 2020 exceeds its currently budgeted expenditures through the third quarter of 2021, there are inherent uncertainties in forecasting future expenditures, especially forecasting for a significantly revised level of operations and with uncertainties such as to how COVID-19 may affect costs and operations. Accordingly, the potential for budget variances in the projection of the Company's planned operations, plus any additional expenditures that may result from unexpected developments, such as additional expenditures that might result from additional legal costs and unexpected fees relating to ongoing legal matters (see Note 5). Taking into account these uncertainties, it raises substantial doubt about the Company's ability to continue as a going concern for the 12 months following the date of this filing.

To the extent these recent cost-cutting measures do not provide sufficient liquidity for the next 12 months, the Company will consider additional equity raises and delaying certain expenditures, including research and development expenses, until sufficient capital becomes available.

At September 30, 2020, the Company had approximately \$17.4 million in cash and had a working capital surplus of approximately \$15.8 million. The Company's net cash used in operating activities during the nine months ended September 30, 2020 was approximately \$5.6 million, and current projections indicate that the Company will have continued negative cash flows until the commercialization of its nuclear fuel. Net losses incurred for the nine months ended September 30, 2020 and 2019 amounted to approximately \$7.5 million and \$8.9 million, respectively. As of September 30, 2020, the Company has an accumulated deficit of approximately \$121.5 million, representative of recurring losses since inception. The Company has incurred recurring losses since inception because it is a development stage nuclear fuel development company. The Company expects to continue to incur losses due to future costs and expenses related to the Company's research and development expenses and general and administrative expenses.

The Company also may consider other plans to fund operations including: (1) raising additional capital through equity issuances or debt financings; (2) additional funding through new relationships to help fund future research and development costs; and (3) other sources of capital. The Company may issue securities, including common stock, preferred stock, and stock purchase contracts through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-3 filed with the SEC on March 15, 2018 and declared effective on March 23, 2018. There can be no assurance as to the availability or terms upon which financing and capital might be available. The Company's future liquidity needs, and ability to address those needs, will largely be determined by the success of the development of its nuclear fuel, key nuclear development and regulatory events, and its business decisions in the future.

Equity Method Investment – Enfission, LLC - Joint Venture with Framatome Inc.

In January 2018, Lightbridge and Framatome Inc., a subsidiary of Framatome SAS (formerly part of AREVA SAS) (collectively "Framatome"), finalized and launched Enfission, LLC ("Enfission"), a 50-50 joint venture company, to develop, license, and sell nuclear fuel assemblies based on Lightbridge-designed metallic fuel technology and other advanced nuclear fuel intellectual property. Lightbridge and Framatome began joint fuel development and regulatory licensing work under previously signed agreements initiated in March 2016. The joint venture, Enfission, is a Delaware-based limited liability company that was formed on January 24, 2018.

Management determined that its investment in Enfission be accounted for under the equity method of accounting. Under the equity method of accounting, an investee company's accounts are not reflected within the Company's condensed consolidated balance sheets and condensed consolidated statements of operations; however, the Company's share of the losses of the investee company is reported in the "Equity in loss from joint venture" line item in the condensed consolidated statements of operations, and the Company's carrying value in an equity method investee company is reported in the "Investment in joint venture" or "Investee losses in excess of investment" line item in the condensed consolidated balance sheets.

The Company allocates income or loss utilizing the hypothetical liquidation book value ("HLBV") method, based on the change in each JV member's claim on the net assets of the JV under the JV's operating agreement at period end after adjusting for any distributions or contributions made during such period. The Company uses this method because of the difference between the distribution rights and priorities set forth in the Enfission operating agreement and what is reflected by the underlying percentage ownership interests of the joint venture.

The Company evaluates on a quarterly basis whether our investment accounted for under the equity method of accounting has an other than temporary impairment ("OTTI"). An OTTI occurs when the estimated fair value of an investment is below the carrying value and the difference is determined not likely to be recoverable. This evaluation requires significant judgment regarding, but not limited to, the severity and duration of the impairment; the ability and intent to hold the security until recovery; financial condition, liquidity, and near-term prospects of the issuer; specific events; and other factors.

Enfission was inactive as of September 30, 2020 and December 31, 2019. No amounts related to the equity method investment in Enfission have been recorded on the condensed consolidated balance sheets or the condensed consolidated statements of operations for the three and nine months ended September 30, 2020.

Basis of Consolidation

These condensed consolidated financial statements include the accounts of Lightbridge, a Nevada corporation, and the Company's wholly-owned subsidiaries, TPI, a Delaware corporation, and Lightbridge International Holding LLC, a Delaware limited liability company. These wholly-owned subsidiaries are inactive. All significant intercompany transactions and balances have been eliminated in consolidation.

The Company owns a 50% interest in Enfission, accounted for using the equity method of accounting (see Note 3, Investment in Joint Venture (Investee Losses in Excess of Investment)). Investment in Joint Venture (Investee Losses in Excess of Investment). Enfission is deemed to be a variable interest entity ("VIE") under the VIE model of consolidation because it does not have sufficient funds to finance its operations. The Company has determined that it is not the primary beneficiary of the VIE since it does not have the power to direct the activities that most significantly impact the VIE's performance.

In determining whether the Company is the primary beneficiary and whether it has the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIE, the Company evaluates all its economic interests in the entity, regardless of form. This evaluation considers all relevant factors of the entity's structure including the entity's capital structure, contractual rights to earnings (losses) as well as other contractual arrangements that have potential to be economically significant. The Company is not the primary beneficiary since the major decision making for all significant economic activities require the approval of both the Company and Framatome. The significant economic activities identified were financing activities, research and development activities, licensing activities, manufacturing of fuel assembly product activities, and marketing and sales activities. The evaluation of each of these factors in reaching a conclusion about the potential significance of our economic interests and control is a matter that requires the exercise of management judgment.

Certain Risks, Uncertainties and Concentrations

The Company is an early stage company and will need additional funding by way of strategic alliances, government grants, further offerings of equity securities, an offering of debt securities, or a financing through a bank in order to support the remaining research and development activities required to further enhance and complete the development of its fuel products to a commercial stage.

The Company participates in a government-regulated industry. Our operating results are affected by a wide variety of factors including decreases in the use or public favor of nuclear power, the ability of our technology to safeguard the production of nuclear power, the ability to receive the required approval from the nuclear regulatory commission for utilities to use our fuel and our ability to safeguard our patents and intellectual property from competitors. Due to these factors, the Company may experience substantial period-to-period fluctuations in our future operating results. Potentially, a loss of key officer, key management, and other personnel could impair our ability to successfully execute our business strategy, particularly when these individuals have acquired specialized knowledge and skills with respect to nuclear power and our operations.

Our future operations and earnings may depend on the results of the Company's operations outside the United States, including some of its research and development activities. There can be no assurance that the Company will be able to successfully continue to conduct such operations, and a failure to do so would have a material adverse effect on the Company's research and development activities, financial position, results of operations, and cash flows. Also, the success of the Company's operations will be subject to other numerous contingencies, some of which are beyond management's control. These contingencies include general and regional economic conditions, competition, changes in government regulations and support for nuclear power, changes in accounting and taxation standards, inability to achieve overall long-term goals, future impairment charges, and global or regional catastrophic events. The Company may be subject to various additional political, economic, and other uncertainties.

[Table of Contents](#)

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risk to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak a pandemic, based on increase in exposure globally. The current spread of COVID-19 that is impacting global economic activity and market conditions could lead to adverse changes in our ability to conduct research and development activities with the United States national labs and others. The recent COVID-19 pandemic has impacted our business operations and results of operations for the first nine months of 2020, resulting in the reduction of our research and development expenses and increase in our general and administrative expenses due to severance payments to our former employees. While we continue to monitor the impact of COVID-19 on our business, we are unable to accurately predict the ultimate impact on our results of operations, financial condition and liquidity that COVID-19 will have due to various uncertainties, including the geographic spread of the virus, the severity of the disease, the duration of the outbreak, and actions that may be taken by governmental authorities and other third-parties.

On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payment, net operating loss carryback period, alternative minimum tax credit refund, modification to the net interest deduction limitation, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation method for qualified improvement property. It also appropriated funds for the SBA Paycheck Protection Program loans that are forgivable in certain situations to promote continued employment, as well as Economic Injury Disaster Loans to provide liquidity to small businesses harmed by COVID-19. Management decided not to apply for these funds. We continue to examine the impact that the CARES Act may have on our results of operations, financial condition and liquidity.

Cash and Cash Equivalents

The Company may at times invest its excess cash in interest bearing accounts and US Treasury Bills. It classifies all highly liquid investments with original stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. The Company holds cash balances in excess of the federally insured limits of \$250,000. It deems this credit risk not to be significant as cash is held by two prominent financial institutions in 2020 and 2019. The Company buys and holds short-term US Treasury Bills from Treasury Direct to maturity. US Treasury Bills totaled approximately \$13.0 million and \$9.0 million at September 30, 2020 and December 31, 2019, respectively. The remaining \$4.4 million and \$9.0 million at September 30, 2020 and December 31, 2019, respectively, are on deposit with one notable financial institution. Total cash and cash equivalents held, as reported on the accompanying condensed consolidated balance sheets, totaled approximately \$17.4 million and \$18.0 million at September 30, 2020 and December 31, 2019, respectively.

Grant Income

The Company has concluded that its government grant is not within the scope of ASC Topic 606 as it does not meet the definition of a contract with a customer. Additionally, the Company has concluded that the grant meets the definition of a contribution and are non-reciprocal transactions, and has also determined that Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grant is with governmental agencies.

In the absence of applicable guidance under US GAAP, the Company management has developed a policy to recognize grant income at the time the related costs are incurred and the right to payment is realized.

The Company believes this policy is consistent with the overarching premise in ASC Topic 606, to ensure that revenue recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that we expect to be entitled to in exchange for those goods or services, even though there is no exchange as defined in ASC Topic 606. Additionally, the Company has determined that the recognition of grant income as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC Topic 606.

Further, the Company believes that showing grant income on a gross method, with the grant income shown as other operating income and the related costs as a charge to research and development expense, rather than depicting the grant income as a reduction of research and development expense, is a more meaningful presentation.

The Company recognized grant income of approximately \$30,000 for the three and nine months ended September 30, 2020. There was no grant income recognized in 2019.

Recently Adopted Accounting Pronouncements

Intangibles, Goodwill and Other — In January 2017, the Financial Accounting Standards Board (FASB) issued ASU 2017-04, *Intangibles – Goodwill and Other (Topic 350) – Simplifying the Test for Goodwill Impairment*. To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, ASU 2017-04 requires an entity to perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019. The Company adopted ASU 2017-04 commencing in the first quarter of fiscal 2020 and this ASU did not have a material impact on its condensed consolidated financial statements and related footnote disclosures.

ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement — This ASU modifies the disclosure requirements on fair value measurements in Topic 820, including the removal, modification to, and addition of certain disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The majority of the disclosure changes are to be applied on a prospective basis. The Company adopted ASU 2018-13 commencing in the first quarter of fiscal 2020 and this ASU did not have a material impact on the Company's fair value disclosures in the Company's condensed consolidated financial statements.

ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The ASU also clarifies and amends existing guidance to improve consistent application. For public business entities, the amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The amendments in the ASU have various transition requirements.

Recent Accounting Pronouncements – To Be Adopted

The Company does not believe that other standards, which have been issued but are not yet effective, will have a significant impact on its condensed consolidated financial statements and related footnote disclosures.

Note 2. Net Loss Per Share

Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period except that it does not include unvested common shares subject to repurchase or cancellation. Diluted net income per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options, warrants and convertible preferred shares (see Note 7, Stockholders' Equity and Stock-Based Compensation). The dilutive effect of outstanding stock options, warrants and convertible preferred shares is not reflected in diluted earnings per share because the Company incurred net losses for the three months and nine months ended September 30, 2020 and 2019, and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive, therefore not included in the calculations.

Note 3. Investment in Joint Venture (Investee Losses in Excess of Investment)

Current Status of the Joint Venture - Inactive

Pursuant to the Enfission operating agreement, both partners agreed that Enfission would serve as the vehicle to develop, license, and sell nuclear fuel assemblies based on Company-designed metallic fuel technology and other advanced nuclear fuel intellectual property licensed to Enfission by both the Company and Framatome or their affiliates. The joint venture built upon the joint fuel development and regulatory licensing work under previously signed agreements initiated in March 2016.

On November 18, 2019, the Company delivered to the Board of Directors of Enfission a notice of termination of the R&D Services Agreement, dated November 14, 2017, by and among Framatome, Enfission and the Company (as amended by Amendment Number One, dated January 25, 2018, and Amendment Number Two, dated June 20, 2018, the "RDSA"), which, among other things, defined the terms and conditions for joint research and development activities among Framatome, Enfission, and the Company. The notice terminated the RDSA, effective immediately. On November 23, 2019, in connection with the termination of the RDSA, the Board of Directors and the management of Lightbridge determined that it is advisable and in the best interest of the Company and its shareholders to take the necessary steps to dissolve Enfission. Various corporate and operational matters relating to Enfission are governed pursuant to the Enfission operating agreement. Although Enfission's Board of Directors has not approved a formal dissolution plan as of the date of this filing, Enfission was inactive as of December 31, 2019 and during the nine months ended September 30, 2020 and through the date of this filing.

Equity method

The Enfission operating agreement provided that Lightbridge and Framatome each hold 50% of the total issued Class A voting membership units of the joint venture. The Company's equity in losses are accounted for under the equity method consisted of the following as of September 30, 2020 and December 31, 2019 (rounded in millions):

	September 30, 2020	December 31, 2019
Enfission, LLC		
Ownership Interest	50%	50%
Carrying Amount		
Total contributions	\$ 9.2	\$ 9.2
Less: Share of the loss in investment in Enfission	(9.2)	(9.2)
Equity balance	<u>\$ —</u>	<u>\$ —</u>

The Company invested approximately \$9.2 million in Enfission and Framatome invested approximately \$2.9 million of equity for the period from January 24, 2018 (date of inception of Enfission) to September 30, 2020. There were no contributions made to Enfission for the nine months ended September 30, 2020. The cash balance in Enfission at September 30, 2020 was approximately \$0.2 million. During the nine months ended September 30, 2020, Enfission incurred a loss of approximately \$0.1 million, and in accordance with the provisions in the joint venture operating agreement, the Company did not record its share of the loss in investment in Enfission for the three and nine months ended September 30, 2020.

As of September 30, 2020 and December 31, 2019, the Company's total equity share of the joint venture accumulated losses is limited to the total equity contributions Lightbridge made since January 24, 2018 according to the Enfission joint venture operating agreement. The joint venture operating agreement states that at no time during the term of the company or upon dissolution or liquidation of the company shall a member with a deficit balance in its capital account have any obligation to Enfission or to the other members of Enfission to restore such deficit capital balance, to the fullest extent permitted by applicable law and to the provisions of the joint venture operating agreement. The Company had not separately guaranteed any obligations of Enfission. The Company does not expect to provide additional equity contributions in 2020 nor for the foreseeable future until Enfission is dissolved.

Summarized balance sheet information for the Company's equity method investee Enfission as of September 30, 2020 and December 31, 2019 is presented in the following table (rounded in millions):

	September 30, 2020	December 31, 2019
Assets		
Cash	\$ 0.2	\$ 1.0
Other current assets	—	—
Total assets	<u>\$ 0.2</u>	<u>\$ 1.0</u>
Liabilities and equity		
Total liabilities	\$ 1.3	\$ 2.1
Equity (Deficit)	(1.1)	(1.1)
Total liabilities and equity	<u>\$ 0.2</u>	<u>\$ 1.0</u>

[Table of Contents](#)

Summarized statement of operations information for the Company's equity method investee Enfission is presented in the following table for the nine months ended September 30, 2020 and 2019 (rounded in millions):

	For the Nine Months Ended September 30,	
	2020	2019
Revenue	\$ —	\$ —
Research and development costs	—	4.4
Administrative expenses	0.1	1.0
Total Operating Loss	\$ 0.1	\$ 5.4
Loss from operations	\$ 0.1	\$ 5.4
Net loss	\$ 0.1	\$ 5.4

As of September 30, 2020 and December 31, 2019, the total receivable due from Enfission was approximately \$0 and \$0.4 million, respectively, which represents management and administrative services, consulting fees and reimbursable expenses Lightbridge charged to Enfission in 2019 (see Note 8, Related Party Transactions). Lightbridge did not bill any management and administrative services, consulting fees or other services to Enfission for the three months and nine months ended September 30, 2020, as Enfission was inactive during these reporting periods.

Disputed Invoices

Included in the total liabilities of Enfission of \$1.3 million at September 30, 2020 and \$2.1 million at December 31, 2019, are disputed invoices totalling \$1.3 million for research and development work submitted by Framatome in 2019. These invoices have been disputed by the Company and remain unpaid as of the date of this filing. There are various disagreements between Framatome and Lightbridge regarding these disputed Framatome invoices. It is expected that these disputes will be resolved through either further negotiation by the joint venture partners or in arbitration. The Company had not separately guaranteed any obligations of Enfission at September 30, 2020 and December 31, 2019 and does not believe that it is obligated under the joint venture operating agreement to fund its deficit capital account balance to pay any current or future liabilities incurred and owed by Enfission.

Note 4. Accounts Payable and Accrued Liabilities

Accounts payable and accrued expenses consisted of the following (rounded in millions):

	September 30, 2020	December 31, 2019
Trade payables	\$ 0.1	\$ 0.3
Accrued bonuses	0.7	—
Accrued expenses	1.0	0.1
Total	\$ 1.8	\$ 0.4

Note 5. Commitments and Contingencies

Commitments

Operating Leases

The Company leases office space for a 12-month term with a monthly payment of approximately \$15,000 per month for office rent. The term of the lease was renewed on January 1, 2020 and extends through December 31, 2020.

The future minimum lease payments required under the non-cancellable operating leases at September 30, 2020 total approximately \$45,000.

Contingencies

Litigation

A former Chief Financial Officer of the Company filed a complaint against the Company with the US Occupational Safety and Health Administration ("OSHA") on March 9, 2015. This complaint was dismissed by OSHA in January 2018 without any findings against the Company. On March 14, 2018 an appeal was filed. The Company has and will continue to vigorously defend this appeal and believes that this appeal hearing will not result in any findings against the Company. On September 6, 2019, the Company filed a motion for summary decision seeking a decision in its favor as a matter of law. This motion for summary decision was denied on September 30, 2020. As of September 30, 2020 and December 31, 2019, legal fees of approximately \$2,300 and \$6,000 were owed, respectively, and are expected to be paid in full by the Company's insurance carriers.

Filing of Arbitration

On November 18, 2019, the Company delivered a notice of termination of the RDSA to Framatome, thereby terminating the RDSA, based on the Company's assertion that Framatome materially breached certain material terms of the RDSA, relating to its invoicing obligations, as well as a failure of the escalation process under the RDSA to agree to a budget commitment for 2019-2020. Framatome has contested the Company's right to terminate the RDSA, raised questions as to the Company's rights relating to their co-owned intellectual property and the Company's right to conduct certain research and development activities, and reserved its right to seek compensation from the Company. On this basis and based on the Company's assertion that the conduct of Framatome prevented Enfission from functioning and progressing towards its goals, on February 7, 2020, the Company has filed a request for arbitration (the "Arbitration Request") in the International Court of Arbitration of the International Chamber of Commerce against Framatome. The Company has undertaken this action in order to obtain, inter alia, a declaration that the RDSA was validly terminated and is no longer in force, and to obtain compensation for the damages incurred. Following the termination of the RDSA and the subsequent filing of the Arbitration Request, Lightbridge has reduced its research and development activities as it is no longer conducting research and development activities with Framatome and Enfission.

On April 3, 2020, Framatome submitted its answer to the Arbitration Request, disputing the Company's claims, setting out its own counterclaims against the Company and its request for relief sought from the International Court of Arbitration. The Company believes it has meritorious claims in the arbitration and intends to pursue its interests vigorously.

We have incurred and will continue to incur material legal fees associated with our ongoing arbitration. In making a determination regarding accruals, using available information, we evaluate the likelihood of an unfavorable outcome in legal or regulatory proceedings to which we are a party and record a loss contingency when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. These subjective determinations are based on the status of such legal or regulatory proceedings, the merits of our defenses, and consultation with legal counsel. Actual outcomes of these legal and regulatory proceedings may materially differ from our current estimates. It is possible that resolution of any legal matters currently pending or threatened could result in losses material to our consolidated results of operations, liquidity, or financial condition. The estimated liability that is probable may be adjusted at each reporting period until it is finally settled. As of the date of this filing, it has been determined not to be probable that a liability has been incurred and that the amount of loss can be reasonably estimated.

Note 6. Research and Development Costs

Lightbridge's total corporate research and development costs, included in the caption research and development expenses in the accompanying condensed consolidated statement of operations, amounted to approximately \$0.3 million and \$0.8 million for the three months ended September 30, 2020 and 2019, respectively, and \$0.8 million and \$2.2 million for the nine months ended September 30, 2020 and 2019, respectively. See Note 8, Related Party Transactions, regarding consulting fees charged to Enfission for research and development expenses incurred by Lightbridge on behalf of Enfission in 2019.

On December 19, 2019 the Company was awarded a voucher from the U.S. Department of Energy's (DOE) Gateway for Accelerated Innovation in Nuclear (GAIN) program to support development of Lightbridge Fuel™ in collaboration with Idaho National Laboratory (INL). The scope of the project includes experiment design for irradiation of Lightbridge metallic fuel material samples in the Advanced Test Reactor (ATR) at INL. On April 22, 2020, the Company entered into a Cooperative Research and Development Agreement (CRADA) with Battelle Energy Alliance, LLC, the operating contractor of INL, in collaboration with DOE. Signing the CRADA was the last step in the contracting process to formalize a voucher award from the GAIN program. The project has commenced in the second quarter of 2020. The total project value is approximately \$846,000, with three-quarters of this amount funded by DOE for the scope performed by INL and the remaining amount funded by Lightbridge, by providing in-kind services to the project. For the three and nine months ended September 30, 2020 approximately \$30,000 of work was completed by INL that caused the DOE to incur payment obligations related to the GAIN voucher. This amount was recorded as grant income in other operating income (loss) line item of the condensed consolidated statement of operations and the corresponding amount as research and development expenses. No work was completed by INL for the three and nine months ended September 30, 2019.

Note 7. Stockholders' Equity and Stock-Based Compensation

At September 30, 2020, the Company had 4,416,961 common shares outstanding. Also outstanding were warrants relating to 70,361 shares of common stock, stock options relating to 515,985 shares of common stock, 712,126 shares of Series A convertible preferred stock convertible into 59,344 shares of common stock (plus dividends of \$657,299 relating to an additional 19,954 common shares), and 2,666,667 shares of Series B convertible preferred stock convertible into 222,222 shares of common stock (plus accrued dividends of \$813,285, relating to an additional 45,182 common shares), all totaling 5,350,009 shares of common stock and all common stock equivalents, including accrued preferred stock dividends, outstanding at September 30, 2020.

At December 31, 2019, the Company had 3,252,371 common shares outstanding. Also outstanding were warrants relating to 70,361 shares of common stock, stock options relating to 518,551 shares of common stock, 757,770 shares of Series A convertible preferred stock convertible into 63,148 shares of common stock (plus dividends of \$556,390 relating to an additional 16,890 common shares), and 2,666,667 shares of Series B convertible preferred stock convertible into 222,222 shares of common stock (plus accrued dividends of \$569,181, relating to an additional 31,621 common shares), all totaling 4,175,164 shares of common stock and all common stock equivalents, including accrued preferred stock dividends, outstanding at December 31, 2019.

Common Stock Equity Offerings

ATM Offerings

On May 28, 2019, the Company entered into an at-the-market equity offering sales agreement ("2019 ATM") with Stifel, Nicolaus & Company, Incorporated ("Stifel"), pursuant to which the Company may issue and sell shares of its common stock from time to time through Stifel as the Company's sales agent. Sales of the Company's common stock through Stifel, if any, will be made by any method that is deemed to be an "at-the-market" equity offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-223674) filed on March 15, 2018 and declared effective March 23, 2018. Due to the offering limitations currently applicable to the Company under General Instruction I.B.6. of Form S-3 and the Company's public float as of May 28, 2019, and in accordance with the terms of the sales agreement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to \$13,500,000. See Note 9, Subsequent Events, for additional information on the filing of a prospectus supplement and the increase in the aggregate amount that may be issued and sold under the 2019 ATM.

On March 30, 2018, the Company entered into an at-the-market issuance sales agreement with B. Riley FBR, Inc. ("B. Riley") that superseded the prior at-the-market agreement with B. Riley (collectively, the "2018 ATM"), pursuant to which the Company could issue and sell shares of its common stock from time to time through B. Riley as the Company's sales agent. Effective March 29, 2019, the Company and B. Riley terminated the 2018 ATM agreement.

[Table of Contents](#)

The Company sold 0.6 million shares and 1.1 million shares under the 2019 ATM during the three and nine months ended September 30, 2020, respectively. Net proceeds received from the ATM sales during the three and nine months ended September 30, 2020 were approximately \$2.5 million and \$5.1 million, respectively. The Company records its ATM sales on a settlement date basis. A total of 109,500 shares sold on September 29 and September 30, 2020, for total gross proceeds of \$476,000, were recorded with settlement dates in the first week in October 2020. See Note 9, Subsequent Events, for additional information on ATM sales made after September 30, 2020.

The Company sold 115,527 shares and 508,063 shares under the 2019 ATM and the 2018 ATM during the three and nine months ended September 30, 2019, respectively. Net proceeds received from the ATM sales during the three and nine months ended September 30, 2019 were approximately \$0.8 million and \$3.8 million, respectively. The Company records its ATM sales on a settlement date basis.

Preferred Stock Equity Offerings

Series B Preferred Stock - Securities Purchase Agreement

On January 30, 2018, the Company issued 2,666,667 shares of newly created Non-Voting Series B Convertible Preferred Stock (the "Series B Preferred Stock") and associated warrants to purchase up to 55,555 shares of the Company's common stock to the several purchasers for approximately \$4.0 million or approximately \$1.50 per share of Series B Preferred Stock and associated warrant. Dividends accrue on the Series B Preferred Stock at the rate of 7% per year and will be paid in-kind through an increase in the liquidation preference per share. The liquidation preference, initially \$1.50 per share of Series B Preferred Stock, is the base that is also used to determine the number of common shares into which the Series B Preferred Stock will convert as well as the calculation of the 7% dividend. Each share of Series B Preferred Stock is convertible at the option of the holder into such number of shares of the Company's common stock equal to the liquidation preference divided by the conversion price of \$18 per share subject to adjustments in the case of stock splits and stock dividends.

Holders of the Series B Preferred Stock are also entitled to participating dividends whenever dividends in cash, securities (other than shares of the Company's common stock paid on shares of common stock) or property are paid on common shares or shares of Series A Preferred Stock. The amount of the dividends will equal the amount to which the holder would be entitled if all shares of Series B Preferred Stock had been converted to common stock immediately prior to the record date.

The warrants had a per share of common stock exercise price of \$22.50. The warrants were exercisable upon issuance and expired six months after issuance on July 30, 2018. Warrants were also issued to the investment bank who introduced these investors, which were subsequently transferred to the principal of the investment bank, entitling the holder to purchase 11,119 common shares in the Company at an exercise price of \$18 per share, up to and including January 30, 2021. On February 6, 2017 the Company entered into an agreement with this investment bank. The agreement calls for monthly retainer payments of \$15,000, which are credited against any transaction introductory fee earned by the investment bank. This agreement calls for a 7% transaction introductory fee and warrants equal to 5% of the total transaction amount, at a strike price equal to the offering price for a three-year term.

The holders of the Series B Preferred Stock have no voting rights. In addition, as long as the shares of Series B Preferred Stock are outstanding, the Company may not take certain actions without first having obtained the affirmative vote or waiver of the holders of a majority of the outstanding shares of Series B Preferred Stock. The Company has the option at any time after August 2, 2019 to redeem some or all of the outstanding Series B Preferred Stock for an amount in cash equal to the liquidation preference plus the amount of any accrued but unpaid dividends of the Series B Preferred Stock being redeemed. The holders of the Series B Preferred Stock do not have the ability to require the Company to redeem the Series B Preferred Stock. The Company has not redeemed any of the outstanding Series B Preferred Stock during the nine months ended September 30, 2020 and 2019 and from the date of issuance.

[Table of Contents](#)

The Company has the option of forcing the conversion of all or part of the Series B Preferred Stock if at any time the average closing price of the Company's common stock for a thirty-trading day period is greater than \$65.88 prior to August 2, 2019 or greater than \$98.82 at any time. The Company can exercise this option only if it also requires the conversion of the Series A Preferred Stock in the same proportion as it is requiring of the Series B Preferred Stock. The Company did not force the conversion of any of the outstanding Series B Preferred Stock during the nine months ended September 30, 2020 and 2019 and from the date of issuance.

Of the \$4.0 million proceeds, approximately \$0.3 million was allocated to the warrants with the remaining \$3.7 million allocated to the Series B Preferred Stock. The Series B Preferred Stock was initially convertible into 2,666,667 shares of common stock (now convertible into 222,222 shares of common stock when adjusted for the one-for-twelve reverse stock split on October 21, 2019). The average of the high and low market prices of the common stock on January 30, 2018, the date of the closing of the sale of the Series B Preferred Stock, was approximately \$28.08 per share. At \$28.08 per share the common stock into which the Series B Preferred Stock was initially convertible was valued at approximately \$6.2 million. This amount was compared to the \$3.7 million (rounded) of proceeds allocated to the Series B Preferred Stock to indicate that a beneficial conversion feature ("BCF") of approximately \$2.6 million existed at the date of issuance, which was immediately accreted as a deemed dividend because the conversion rights were immediately effective.

Additionally, comparison of the original \$1.50 conversion price prior to the one-for-twelve reverse stock split on October 21, 2019 of the PIK dividends to the \$2.34 commitment date fair value per share on January 30, 2018 indicates that each PIK dividend will accrete \$0.84 of BCF as an additional deemed dividend for every \$1.50 of PIK dividend accrued. Total deemed dividends for this PIK dividend for the three months ended September 30, 2020 and 2019 were approximately \$46,000 and \$43,000, respectively and for the nine months ended September 30, 2020 and 2019 were approximately \$137,000 and \$128,000, respectively.

The accumulated dividend (unpaid) at September 30, 2020 and December 31, 2019 was approximately \$0.8 million and \$0.6 million, respectively. The Series B Preferred Shares outstanding as of September 30, 2020 and December 31, 2019 was 2,666,667 shares with an aggregate liquidation preference of approximately \$4.8 million and \$4.6 million, including the accumulated dividends at September 30, 2020 and December 31, 2019, respectively.

Series A Preferred Stock - Securities Purchase Agreement

On August 2, 2016, the Company issued 1,020,000 shares of newly created Non-Voting Series A Convertible Preferred Stock (the "Series A Preferred Stock") to General International Holdings, Inc. for \$2.8 million or approximately \$2.75 per share. Dividends accrue on the Series A Preferred Stock at the rate of 7% per year and will be paid in-kind through an increase in the liquidation preference per share. The liquidation preference, initially \$2.7451 per share of Series A Preferred Stock, is the base that is also used to determine the number of common shares into which the Series A Preferred Stock will convert as well as the calculation of the 7% dividend. Each share of Series A Preferred Stock is convertible at the option of the holder into such number of shares of the Company's common stock equal to the liquidation preference divided by the conversion price of \$32.94 per share subject to adjustments in the case of stock splits and stock dividends.

Holders of the Series A Preferred Stock are also entitled to participating dividends whenever dividends in cash, securities (other than shares of the Company's common stock) or property are paid on common shares. The amount of the dividends is the amount to which the holder would be entitled if all shares of Series A Preferred Stock had been converted to common stock immediately prior to the record date.

The Company has the option of forcing the conversion of the Series A Preferred Stock if the trading price for the Company's common stock is more than two times the applicable conversion price (approximately \$32.94 per share) before August 2, 2019, or if the trading price is more than three times the applicable conversion price (approximately \$49.41 per share) at any time. The Company has not redeemed any of the outstanding Series A Preferred Stock during the nine months ended September 30, 2020 and 2019 and from the date of issuance.

[Table of Contents](#)

The Series A Preferred Stock was initially convertible into 1,020,000 shares of common stock (now convertible into 85,000 common shares when adjusted for the one-for-twelve reverse stock split on October 21, 2019). The average of the high and low market prices of the common stock on August 6, 2016, the date of the closing of the sale of the Series A Preferred Stock, was approximately \$39.78 per share. At \$39.78 per share the common stock into which the Series A Preferred Stock was initially convertible was valued at approximately \$3.4 million. This amount was compared to the \$2.8 million of proceeds of the Series A Preferred Stock to indicate that a BCF of approximately \$0.6 million existed at the date of issuance in 2016, which was immediately accreted as a deemed dividend because the conversion rights were immediately effective.

Additionally, comparison of the \$2.7451 original conversion price of the PIK dividends prior to the one-for-twelve reverse stock split on October 21, 2019, to the \$3.315 commitment date fair value per share indicates that each PIK dividend will accrete \$0.5699 of BCF as an additional deemed dividend for every \$2.7451 of PIK dividend accrued. Total deemed dividends for this PIK dividend for each of the three months ended September 30, 2020 and 2019 were approximately \$10,000 and for each of the nine months ended September 30, 2020 and 2019 were approximately \$28,000.

The holders of the Series A Preferred Stock have no voting rights. In addition, as long as 255,000 shares of Series A Preferred Stock are outstanding, the Company may not take certain actions without first having obtained the affirmative vote or waiver of the holders of a majority of the outstanding shares of Series A Preferred Stock. The Company has the option at any time after August 2, 2019 to redeem some or all of the outstanding Series A Preferred Stock for an amount in cash equal to the liquidation preference plus the amount of any accrued but unpaid dividends of the Series A Preferred Stock being redeemed. The holders of the Series A Preferred Stock do not have the ability to require the Company to redeem the Series A Preferred Stock.

On April 16, 2019, the holder of the Series A Preferred Shares converted 27,747 preferred shares into 2,782 common shares.

On October 8, 2019, the holder of the Series A Preferred Shares converted 28,107 preferred shares into 2,922 common shares.

On February 10, 2020, the holder of the Series A Preferred Shares converted 11,875 preferred shares into 1,255 common shares.

On May 15, 2020, the holder of the Series A Preferred Shares converted 17,080 preferred shares into 1,847 common shares.

On August 31, 2020, the holder of the Series A Preferred Shares converted 16,689 preferred shares into 1,846 common shares.

As of September 30, 2020, there were 712,126 Series A Preferred Shares outstanding, with an aggregate liquidation preference of approximately \$2.6 million, including accumulated dividends, while there were 757,770 Series A Preferred Shares outstanding as of December 31, 2019, with an aggregate liquidation preference of approximately \$2.6 million, including accumulated dividends.

Warrants

The Company's outstanding warrants at September 30, 2020 and December 31, 2019 are below. These warrants are classified within equity on the condensed consolidated balance sheets.

<i>Outstanding Warrants</i>	September 30, 2020	December 31, 2019
Issued to Investors on October 25, 2013, entitling the holders to purchase 20,833 common shares in the Company at an exercise price of \$138.00 per common share up to and including April 24, 2021. In 2016, the warrant holders agreed to new warrant terms, which excluded any potential net cash settlement provisions in exchange for a reduced exercise price of \$75.00 per share.	13,665	13,665
Issued to Investors on November 17, 2014, entitling the holders to purchase 45,577 common shares in the Company at an exercise price of \$138.60 per common share up to and including May 16, 2022. On June 30, 2016, the warrant holders agreed to new warrant terms, which excluded any potential net cash settlement provisions in order to classify them as equity in exchange for a reduced exercise price of \$75.00 per share.	45,577	45,577
Issued to an investment bank and subsequently transferred to a principal of the investment bank regarding the Series B Preferred Stock investment on January 30, 2018, entitling the holder to purchase 11,119 common shares in the Company at an exercise price of \$18.00 per share, up to and including January 30, 2021.	11,119	11,119
Total	<u>70,361</u>	<u>70,361</u>

Stock-based Compensation – Stock Options***Adoption of 2020 Stock Plan***

On March 9, 2020, the Board of Directors adopted the Company's 2020 Equity Incentive Plan (the "2020 Plan"). On September 3, 2020, the shareholders approved the 2020 Plan to authorize grants of the following types of awards (a) Options, (b) Stock Appreciation Rights, (c) Restricted Stock and Restricted Stock Units ("RSUs"), and (e) Other Stock-Based and Cash-Based Awards. The shares available for award under the 2020 plan authorized a total of 350,000 shares to be available for grant. See Note 9, Subsequent Events, for additional information on RSU equity grants made under the 2020 Plan after September 30, 2020.

2015 Equity Incentive Plan

On March 25, 2015, the Compensation Committee and Board of Directors approved the Lightbridge Corporation 2015 Equity Incentive Plan (the "2015 Plan") to authorize grants of (a) Incentive Stock Options, (b) Non-qualified Stock Options, (c) Stock Appreciation Rights, (d) Restricted Awards, (e) Performance Share Awards, and (f) Performance Compensation Awards to the employees, consultants, and directors of the Company. The 2015 Plan initially authorized a total of 50,000 shares to be available for grant under the 2015 Plan, of which the amount was increased to 116,667 shares in May 2016, 241,667 shares in May 2017, and 525,000 shares in May 2018.

Short-Term Non-Qualified Option Grants

On December 2, 2019, the Compensation Committee of the Board granted 86,982 short-term incentive stock options and non-qualified stock options under the 2015 Plan to employees, consultants, and directors of the Company. All of these stock options vested immediately, with a strike price of \$3.82, which was the closing price of the Company's stock on December 2, 2019. These options have a 10-year contractual term, with a fair market value of approximately \$2.59 per option with an expected term of 5 years. During the year ended December 31, 2019, the Company issued 4,247 stock options to a consultant. The Company issued 7,634 stock options to a consultant during the nine months ended September 30, 2020.

[Table of Contents](#)

Total stock options outstanding at September 30, 2020 and December 31, 2019 under the 2006 Stock Plan and 2015 Plan were 515,985 and 518,551, of which 466,259 and 433,678 of these options were vested at September 30, 2020 and December 31, 2019, respectively.

The components of stock-based compensation expense (net of forfeitures of stock options) included in the Company's condensed consolidated statements of operations for the three months and nine months ended September 30, 2020 and 2019 are as follows (rounded in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2020	2019	2020	2019
Research and development expenses	—	\$ —	—	\$ 284,000
General and administrative expenses	\$ (4,000)	\$ 20,000	\$ 8,000	\$ 308,000
Total stock-based compensation expense	\$ (4,000)	\$ 20,000	\$ 8,000	\$ 592,000

Stock option transactions to the employees, directors and consultants are summarized as follows for the nine months ended September 30, 2020:

	Options Outstanding	Weighted Average Exercise Price	Weighted Average Grant Date Fair Value
Beginning of the period – January 1, 2020	518,551	\$ 21.99	\$ 15.89
Granted	7,634	4.45	3.28
Exercised	(6,548)	3.82	2.59
Forfeited	(1,844)	10.80	8.33
Expired	(1,808)	501.43	388.45
End of the period – September 30, 2020	515,985	\$ 20.32	\$ 14.60
Options exercisable	466,259	\$ 21.45	\$ 15.36

A summary of the status of the Company's non-vested options as of September 30, 2020 and December 31, 2019, and changes during the nine months ended September 30, 2020, is presented below:

	Shares	Weighted Average Exercise Price	Weighted Average Fair Value Grant Date
Non-vested – January 1, 2020	84,873	\$ 10.73	\$ 5.15
Granted	7,634	4.45	3.28
Vested	(41,552)	10.80	8.29
Forfeited	(1,229)	10.80	8.33
Non-vested – September 30, 2020	49,726	\$ 9.71	\$ 7.44

[Table of Contents](#)

The above tables include options issued and outstanding as of September 30, 2020 as follows:

- i) A total of 393,130 incentive stock options and non-qualified 10-year options have been issued, and are outstanding, to the directors, officers, and employees at an exercise price range of \$3.82 to \$331.80 per share. From this total, 128,010 options are outstanding to the Chief Executive Officer, who is also a director, with remaining contractual lives of 0.5 years to 9.2 years. All other options issued to directors, officers, and employees have a remaining contractual life ranging from 0.5 years to 9.2 years.
- ii) A total of 122,855 non-qualified 10-year options have been issued, and are outstanding, to consultants at an exercise price range of \$3.82 to \$355.80 per share.

As of September 30, 2020, there was approximately \$48,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the equity incentive plans. That cost is expected to be recognized over a weighted-average period of approximately 2.26 years. For stock options outstanding at September 30, 2020 and December 31, 2019, the intrinsic value was approximately \$28,000 and \$59,000, respectively.

The following table provides certain information with respect to the above-referenced stock options that were outstanding and exercisable at September 30, 2020:

Exercise Prices	Stock Options Outstanding			Stock Options Vested		
	Weighted Average Remaining Contractual Life -Years	Number Of Awards	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life -Years	Number of Awards	Weighted Average Exercise Price
\$ 3.82-\$12.48	8.41	225,179	\$ 8.04	8.46	176,332	\$ 7.60
\$ 12.49-\$24.00	6.82	199,790	\$ 14.19	6.81	198,911	\$ 14.20
\$ 24.01-\$72.00	5.14	65,333	\$ 55.07	5.14	65,333	\$ 55.07
\$ 72.01-\$240.00	4.57	24,526	\$ 75.59	4.57	24,526	\$ 75.59
\$ 240.01-\$355.80	0.43	1,157	\$ 332.91	0.43	1,157	\$ 332.91
Total	7.18	<u>515,985</u>	\$ 20.32	7.07	<u>466,259</u>	\$ 21.45

Note 8. Related Party Transactions

Enfission was inactive at September 30, 2020 and December 31, 2019. The Company did not invest in Enfission during the nine months ended September 30, 2020 and invested approximately \$9.2 million in Enfission from Enfission's date of inception of January 24, 2018 to December 31, 2019.

The Company did not charge Enfission an administrative and management services fee for the three months and nine months ended September 30, 2020. The total administrative consulting services was \$0.1 million and \$0.3 million for the three months and nine months ended September 30, 2019, respectively. For the three months ended September 30, 2019, the \$0.1 million amount charged was recorded as a \$50,000 reduction of general and administrative expenses and a \$50,000 reduction of research and development expenses. For the nine months ended September 30, 2019, the \$0.3 million amount charged was recorded as a \$150,000 reduction of general and administrative expenses and a \$150,000 reduction of research and development expenses.

The Company did not provide Enfission with any research and development consulting services for the three months and nine months ended September 30, 2020. The Company provided research and development consulting services and management services to Enfission in 2019. The total consulting services income was \$0.2 million and \$0.9 million for the three months and nine months ended September 30, 2019, respectively, recorded under "Other income from joint venture" in the accompanying condensed consolidated statement of operations.

As of September 30, 2020, there was no receivable due from Enfission. At December 31, 2019, the total receivable due from Enfission was approximately \$0.4 million, which represented management and administrative services Lightbridge charged to Enfission for the year ended December 31, 2019.

Note 9. Subsequent Events

ATM

On October 9, 2020, the Company updated the aggregate amount that may be issued and sold under the 2019 ATM from \$13.5 million to approximately \$14.7 million by filing a prospectus supplement pursuant to which the Company registered an additional approximate \$1.2 million of shares of common stock. As of the date of this filing, the Company has sold a total of \$12.0 million of shares of common stock pursuant to the 2019 ATM sales agreement.

Sales under the 2019 ATM that were made from October 1, 2020 to November 5, 2020 were approximately 1.2 million shares that totaled net proceeds of approximately \$4.7 million.

Equity Grants

On October 28, 2020, the Compensation Committee of the Board granted time-based RSUs to certain of the Company's executive officers, employees, and consultants. Each RSU represents a contingent right to receive, upon vesting, one share of the Company's Common Stock. The number of RSUs granted to executive officers, employees and consultants totaled 243,800. These RSU awards granted vest in three equal installments on each of the first three anniversaries of the grant date, on October 28, 2021, October 28, 2022 and October 28, 2023. On the same date, the Compensation Committee of the Board approved a grant of a total of 21,200 shares of common stock to the Company's four directors. All of these shares vest on November 10, 2020.

FORWARD-LOOKING STATEMENTS

In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. We use words such as “believe”, “expect”, “anticipate”, “project”, “target”, “plan”, “optimistic”, “intend”, “aim”, “will”, or similar expressions, which are intended to identify forward-looking statements. Such statements include, among others:

- those concerning market and business segment growth, demand, and acceptance of our nuclear fuel technology and other steps to commercialization of Lightbridge Fuel™;
- any projections of sales, earnings, revenue, margins, or other financial items;
- any statements of the plans, strategies, and objectives of management for future operations and the timing and outcome of the development of our nuclear fuel technology;
- any statements regarding future economic conditions or performance;
- uncertainties related to conducting business in foreign countries;
- any statements relating to the outcome of the arbitration with Framatome;
- any statements about future financings and liquidity the Company’s anticipated financial resources and position; and
- all assumptions, expectations, predictions, intentions, or beliefs about future events and other statements that are not historical facts.

You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, as well as assumptions that if they were to ever materialize or prove incorrect, could cause the results of the Company to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties, among others, include:

- our ability to commercialize our nuclear fuel technology, including risks related to the design and testing of nuclear fuel incorporating our technology;
- the dissolution of Enfission, LLC our joint venture with Framatome Inc., including associated costs and the timing of the dissolution, our ability to conduct research and development activities in the future within the scope of operations of the joint venture and our retention of certain intellectual property used in the joint venture;
- our ability to attract new customers;
- our ability to employ and retain qualified employees and consultants that have experience in the nuclear industry;
- competition and competitive factors in the markets in which we compete;
- public perception of nuclear energy generally;

[Table of Contents](#)

- risks associated with the further spread and uncertainty of COVID-19, including the ultimate impact of COVID-19 on people, economies, our ability to access capital markets, the Company's financial position, results of operations or liquidity;
- changes in laws, rules, and regulations governing our business;
- development and utilization of, and challenges to, our intellectual property;
- potential and contingent liabilities; and
- the other risks identified in Item 1A. *Risk Factors* included herein and in our Annual Report on Form 10-K for the year ended December 31, 2019.

Most of these factors are beyond our ability to predict or control and you should not put undue reliance on any forward-looking statement. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward-looking statements. Forward-looking statements speak only as of the date on which they are made. The Company assumes no obligation and does not intend to update these forward-looking statements for any reason after the date of the filing of this report, to conform these statements to actual results or to changes in our expectations, except as required by law.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management's Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, is intended to help the reader understand Lightbridge Corporation, our operations and our present business environment. MD&A is provided as a supplement to, and should be read in conjunction with, our condensed consolidated financial statements and the accompanying notes thereto contained in Part I, Item 1 of this report.

This MD&A consists of the following sections:

- Overview of Our Business and recent developments — a general overview of our business and updates;
- Critical Accounting Policies and Estimates — a discussion of accounting policies that require critical judgments and estimates;
- Operations Review — an analysis of our condensed consolidated results of operations for the periods presented in our condensed consolidated financial statements; and
- Liquidity, Capital Resources, and Financial Position — an analysis of our cash flows, and an overview of our financial position.

As discussed in more detail under "Forward-Looking Statements" immediately preceding this MD&A, the following discussion contains forward-looking statements that involve risks, uncertainties, and assumptions such as statements of our plans, objectives, expectations, and intentions. Our actual results may differ materially from those discussed in these forward-looking statements because of the risks and uncertainties inherent in future events.

OVERVIEW OF OUR BUSINESS

When used in this Quarterly Report on Form 10-Q, the terms "Lightbridge", the "Company", "we", "our", and "us" refer to Lightbridge Corporation together with its wholly-owned subsidiaries Lightbridge International Holding LLC and Thorium Power Inc.

Overview

We are an innovative nuclear fuel technology company. Our goal is to develop and commercialize the next generation of nuclear fuel that could significantly improve the economics, safety, and proliferation resistance of nuclear fuel in existing and new nuclear reactors, large and small, with a meaningful impact on addressing climate change, air pollution and benefiting national security. We project that the world's energy and climate needs can only be met if nuclear power's share of the energy-generating mix grows substantially.

We believe our metallic fuel offers significant economic and safety benefits over traditional fuel, primarily because of the superior heat transfer properties of all-metal fuel and the resulting lower operating temperature of the fuel. We also believe that uprating a reactor with Lightbridge Fuel™ will add incremental electricity at a lower levelized cost than any other means of generating baseload electric power, including any renewable, fossil, or hydroelectric energy source, or with any other nuclear fuel.

We have built a significant portfolio of patents reflecting years of research and development, and we anticipate substantial completion of our research efforts in the coming years and the testing of our fuel through third party vendors and others, including the United States Department of Energy National Laboratories.

Our Nuclear Fuel

Since 2008, we have been engaged in the design and development of proprietary, innovative nuclear fuels to improve the cost competitiveness, safety, proliferation resistance and performance of nuclear power generation. In 2010, we announced the concept of all-metal fuel (i.e., non-oxide fuel) for currently operating as well as new-build reactors. Our focus on metallic fuel is based on listening to the voices of prospective customers, as nuclear utilities have expressed interest in the improved economics and enhanced safety that we believe metallic fuel will provide.

The fuel in a nuclear reactor generates heat energy. That heat is then converted through steam into electricity that is sold. We have designed our innovative, proprietary metallic fuels to be capable of significantly higher burnup and power density compared to conventional oxide nuclear fuels. Burnup is the total amount of electricity generated per unit mass of nuclear fuel and is a function of the power density of a nuclear fuel and the amount of time the fuel operates in the reactor. Power density is the amount of heat power generated per unit volume of nuclear fuel. Conventional oxide fuel used in existing commercial reactors is nearing the limit of its burnup and power density capability. As a result, further optimization to increase power output from the same core size and improve the economics and safety of nuclear power generation using conventional oxide fuel technologies is limited. A new fuel is needed to bring enhanced performance to reactors; we are developing that new fuel.

As the nuclear industry prepares to meet the increasing global demand for electricity production, longer operating cycles and higher reactor power outputs have become a much sought-after solution for the current and future reactor fleet. We believe our proprietary nuclear fuel designs have the potential to improve the nuclear power industry's economics by:

- providing an increase in power output of potentially up to 10% while simultaneously extending the operating cycle length from 18 to 24 months in existing pressurized water reactors (PWRs), including in Westinghouse-type four-loop PWR plants which are currently constrained to an 18-month operating cycle by oxide fuel enriched up to 5%, or increasing the power potentially up to 17% while retaining an 18-month operating cycle; and
- enabling increased reactor power output via a power uprate (potentially up to a 30% increase) or a longer operating cycle (instead of a power uprate) without changing the core size in new build PWRs.

We believe our fuel designs will allow current and new build nuclear reactors to safely increase power production and reduce operations and maintenance costs on a per kilowatt-hour basis. New build nuclear reactors could also benefit from the reduced upfront capital investment per kilowatt of generating capacity in the case of implementing a power uprate. In addition to projected electricity production cost savings, we believe our technology can result in utilities or countries needing to deploy fewer new reactors to generate the same amount of electricity (in the case of a power uprate), resulting in significant capital cost savings. For utilities or countries that already have operating reactors, our technology could be utilized to both increase the power output of those reactors as well as enable them to load follow with electric grid demands, which have become increasingly variable with large additions of intermittent renewable generation.

Nuclear Power as Clean and Low Carbon Emissions Energy Source

Nuclear power provides clean, reliable baseload electricity. According to the World Nuclear Association (WNA), nuclear power plants produce no greenhouse gas emissions during operation, and over the course of its lifecycle, nuclear produces about the same amount of CO₂ equivalent emissions per unit of electricity as wind. The WNA further notes that almost all proposed pathways to achieving significant decarbonization suggest an increased role for nuclear power, including those published by the International Energy Agency, Massachusetts Institute of Technology Energy Initiative, US Energy Information Administration, and World Energy Council.

[Table of Contents](#)

We believe that deep cuts to CO2 emissions are only possible with electrification of most of the transportation and industrial sectors globally and powering them and the current electricity needs of the world with non-emitting or low-emitting power. We believe this can be done only with a large increase in nuclear power, several times the amount that is generated globally today. We believe that our nuclear fuel technology will be an essential element of reaching this goal.

Development of Lightbridge Fuel™

Recent Developments

- Entered into a Cooperative Research and Development Agreement (CRADA) on April 22, 2020 with Battelle Energy Alliance, LLC, the operating contractor of INL, in collaboration with DOE. Signing the CRADA was the last step in the contracting process to formalize a voucher award from the U.S. Department of Energy's (DOE) Gateway for Accelerated Innovation in Nuclear (GAIN) program. The scope of the project includes experiment design for irradiation of Lightbridge metallic fuel material samples in the Advanced Test Reactor (ATR) at INL. The project has commenced in the second quarter of 2020. The total project value is approximately \$846,000, with three-quarters of this amount funded by DOE for the scope performed by INL.

Future Steps Toward the Development and Sale of Nuclear Fuel Assemblies

We anticipate near-term fuel development milestones for Lightbridge Fuel™ over the next 12-24 months will consist of the following:

- Complete the scope of work relating to the recent GAIN Voucher award in collaboration with Idaho National Laboratory;
- Enter into an agreement to manufacture our nuclear fuel material samples for test reactor irradiation; and
- Begin the initial demonstration of our manufacturing technology using depleted or natural uranium.

The long-term milestones towards development and sale of nuclear fuel assemblies include, among other things, irradiating material samples and/or prototype fuel rods in test reactors, conducting post-irradiation examination of irradiated material samples and/or prototype fuel rods, performing thermal-hydraulic experiments, performing seismic and other out-of-reactor experiments, entering into a lead test rod/assembly agreement with a host reactor, demonstrating the production of lead test rods and/or lead test assemblies at a pilot-scale fuel fabrication facility and demonstrating the operation of lead test rods and/or lead test assemblies in commercial reactors. There are inherent uncertainties in the cost and outcomes of the many steps needed for successful deployment of our fuel in commercial nuclear reactors, which makes it difficult to predict the timing of the commercialization of our nuclear fuel technology with any accuracy. We will continue to seek development funding contributions or other financing arrangements with utilities and the DOE.

Impact of COVID-19 to our Business

The recent COVID-19 pandemic has impacted our business operations and results of operations for the first nine months of 2020, resulting in the reduction of our research and development expenses and an increase in our general and administrative expenses due to severance payments made to former employees, as described in more detail under "Results of Operations", below. The future impacts of the global emergence of COVID-19 on our financial position, results of operations and future liquidity and capital resources availability is unknown and uncertain.

[Table of Contents](#)

In an effort to protect the health and safety of our employees, we took proactive, aggressive action from the earliest signs of the outbreak in China including working from home and suspending employee travel. In an effort to contain COVID-19 or slow its spread, governments around the world have also enacted various measures, including orders to close all businesses not deemed “essential,” isolate residents to their homes or places of residence, and practice social distancing when engaging in essential activities.

We will continue to actively monitor the COVID-19 situation and may take further actions altering our business operations that we determine are in the best interests of our employees and stakeholders, or as required by federal, state, or local authorities. It is not clear what the potential effects any such alterations or modifications may have on our financial position, results of operations or liquidity, including the effects on our employees and future prospects, including our research and development activities for the remainder of fiscal 2020 and beyond.

Filing of Arbitration

On February 7, 2020, we filed a request for arbitration (the “Arbitration Request”) in the International Court of Arbitration of the International Chamber of Commerce against Framatome, seeking to obtain, inter alia, a declaration that the R&D Services Agreement, dated November 14, 2017, by and among Framatome, Enfission, and the Company (as amended by Amendment Number One, dated January 25, 2018, and Amendment Number Two, dated June 20, 2018, the “RDSA”) was validly terminated and is no longer in force, and to obtain compensation for the damages incurred. Our legal costs have increased in 2020 due to this legal action.

See Part II. Item 1. Legal Proceedings, for more information.

Certain Challenges

Please see Part I, Item 1, “Description of Business—Certain Challenges” in the Annual Report on Form 10-K and Item 1A. Risk Factors in this report and the Annual Report on Form 10-K for a discussion of certain risks and challenges that may delay or impair the development of Lightbridge Fuel™ including without limitation the availability of financing, events related to the dissolution of our joint venture with Framatome, and the many risks inherent in developing a new type of nuclear fuel.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements. For a discussion of the accounting judgments and estimates that we have identified as critical in the preparation of our financial statements, please see “Critical Accounting Policies and Estimates” under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed on March 18, 2020. There have been no significant changes in our critical accounting policies and estimates during the nine months ended September 30, 2020.

Our management expects to make judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operations and/or financial condition.

Recent Accounting Standards and Pronouncements

Refer to Note 1 to our unaudited condensed consolidated financial statements for a discussion of recent accounting standards and pronouncements.

OPERATIONS REVIEW

Financial information is included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Our goal is to develop and commercialize innovative, proprietary nuclear fuel designs, which we expect will significantly enhance the nuclear power industry's economics due to higher power output and improved safety margins.

Our metallic fuel can be used in different types of water-cooled commercial power reactors, such as pressurized water reactors, boiling water reactors, Russian-type VVER reactors, CANDU heavy water reactors, water-cooled small modular reactors, as well as water-cooled research reactors.

We have obtained patent validation in key countries and will continue to seek patent validation in key countries that either currently operate or are expected to build and operate a large number of suitable nuclear power reactors.

We currently expect to invest a total of \$2.0 million to \$3.0 million in the development of our nuclear fuel products, including corporate research and development expenditures, over the next 12 to 15 months.

Condensed Consolidated Results of Operations – Three Months Ended September 30, 2020 and 2019

The following table presents our historical operating results and the increase (decrease) in amounts for the periods indicated:

	Three Months Ended		Increase (Decrease) Change \$	Increase (Decrease) Change %
	September 30,			
	2020	2019		
Operating Expenses				
General and administrative	\$ 2,835,471	\$ 1,463,568	\$ 1,371,903	94%
Research and development expenses	\$ 261,898	\$ 751,473	\$ (489,575)	-65%
Total Operating Expenses	\$ 3,097,369	\$ 2,215,041	\$ 882,328	40%
Other Operating Income and (Loss)				
Grant income	\$ 29,662	\$ —	\$ 29,662	100%
Other income from joint venture	\$ —	\$ 247,568	\$ (247,568)	-100%
Equity in loss from joint venture	\$ —	\$ (555,113)	\$ 555,113	-100%
Total Other Operating Income (Loss)	\$ 29,662	\$ (307,545)	\$ 337,207	-110%
Total Operating Loss	\$ (3,067,707)	\$ (2,522,586)	\$ 545,121	22%
Other Income	\$ 4,645	\$ 81,172	\$ (76,527)	-94%
Net loss before Income Taxes	\$ (3,063,062)	\$ (2,441,414)	\$ 621,648	25%
Net Loss	\$ (3,063,062)	\$ (2,441,414)	\$ 621,648	25%

Operating Expenses

General and Administrative Expenses

General and administrative expenses consist mostly of compensation and related costs for personnel and facilities, stock-based compensation, finance, human resources, information technology, and fees for consulting and other professional services. Professional services are principally comprised of legal, audit, strategic advisory services, and outsourcing services.

Total general and administrative expenses increased by approximately \$1.4 million for the three months ended September 30, 2020, as compared to the three months ended September 30, 2019. There was an increase in professional fees of approximately \$1.3 million primarily due to legal fees relating to the Framatome arbitration and a net increase in employee compensation and employee benefits of approximately \$0.1 million.

See Note 7, Stockholders' Equity and Stock-Based Compensation, of the Notes to our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for more information regarding our stock-based compensation.

Research and Development

Research and development expenses in 2020 and 2019 consist primarily of employee compensation and related fringe benefits including stock-based compensation, and consulting fees, including work performed and billed to our Enfission joint venture in 2019.

Total research and development expenses decreased by approximately \$0.5 million for the three months ended September 30, 2020, as compared to the three months ended September 30, 2019, due to the transitioning from work relating to Enfission to developing a new fuel development strategy with U.S. Department of Energy national laboratories. There was a decrease in allocated employee compensation and employee benefits of approximately \$0.4 million and a decrease in consulting fees of \$0.1 million.

Due to the nature of our research and development expenditures, cost and schedule estimates are inherently uncertain and can vary significantly as new information and the outcome of these research and development activities become available. During the first nine months of 2020, we had a significant decrease in research and development expense compared to 2019, also partially due to the uncertainty of COVID-19 on our future business operations, resulting in budgetary constraints due primarily to current market conditions and the uncertainty of future liquidity and capital resources available to us to conduct our future research and development activities.

Other Operating Income and (Loss)

Reported in other operating income and (loss) is other income for activities performed by our employees and consultants billed to the Enfission joint venture for research and development work and our share of the allocated loss in Enfission. Enfission was inactive at September 30, 2020 and December 31, 2019 and no consulting services were performed on behalf of Enfission for the three months ended September 30, 2020. Therefore, no amounts related to the equity method investment in Enfission have been recorded on the condensed consolidated statements of operations for the three months ending September 30, 2020. As such, total other operating loss decreased by approximately \$0.3 million for the three months ended September 30, 2020, as compared to the three months ended September 30, 2019.

Other income from the Enfission joint venture decreased by approximately \$0.2 million for the three months ended September 30, 2020 as compared to the three months ended 2019. Equity in loss from the Enfission joint venture decreased by approximately \$0.5 million for the three months ended September 30, 2020 as compared to the three months ended 2019, which consists of our share of the allocated loss in Enfission in 2019.

During the three months ended September 30, 2020, the Company did not provide additional equity contributions or share in any loss in Enfission. The Company had not separately guaranteed any obligations of Enfission at September 30, 2020 and December 31, 2019 and does not believe that it is obligated under the joint venture operating agreement to fund its deficit capital account balance in Enfission to pay for any liabilities incurred by Enfission and therefore did not record its share of losses in Enfission at September 30, 2020 and December 31, 2019.

[Table of Contents](#)

There was an increase in grant income of approximately \$30,000 for the three ended September 30, 2020 with a charge to research and development expenses and a corresponding amount to other income. There was no grant income in 2019.

Other Income

There was a decrease in other income of approximately \$0.1 million due to a decrease in interest income generated from the interest earned from the purchase of treasury bills and from our bank savings account for the three months ended September 30, 2020, as compared to the three months ended September 30, 2019.

Provision for Income Taxes

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company is currently evaluating the impact of the CARES Act, but at present does not expect that the NOL carryback provision of the CARES Act would result in a material cash benefit to us. We incurred a pre-tax net loss for both 2020 and 2019. We reviewed all sources of income for purposes of recognizing the deferred tax assets and concluded a full valuation allowance for 2020 and 2019 was necessary. Therefore, we did not have a provision for taxes for the three months and nine months ended September 30, 2020 and 2019.

Condensed Consolidated Results of Operations – Nine Months Ended September 30, 2020 and 2019

The following table presents our historical operating results and the increase (decrease) in amounts for the periods indicated:

	Nine Months Ended September 30,		Increase (Decrease)	Increase (Decrease)
	2020	2019	Change \$	Change %
Operating Expenses				
General and administrative	\$ 6,800,892	\$ 4,051,484	\$ 2,749,408	68%
Research and development expenses	\$ 767,498	\$ 2,218,826	\$ (1,451,328)	-65%
Total Operating Expenses	\$ 7,568,390	\$ 6,270,310	\$ 1,298,080	21%
Other Operating Income and (Loss)				
Grant income	\$ 29,662	\$ —	\$ 29,662	100%
Other income from joint venture	\$ —	\$ 908,224	\$ (908,224)	-100%
Equity in loss from joint venture	\$ —	\$ (3,812,463)	\$ 3,812,463	-100%
Total Other Operating Income (Loss)	\$ 29,662	\$ (2,904,239)	\$ 2,933,901	-101%
Total Operating Loss	\$ (7,538,728)	\$ (9,174,549)	\$ (1,635,821)	-18%
Other Income	\$ 79,474	\$ 315,691	\$ (236,217)	-75%
Net loss before Income Taxes	\$ (7,459,254)	\$ (8,858,858)	\$ (1,399,604)	-16%
Net Loss	\$ (7,459,254)	\$ (8,858,858)	\$ (1,399,604)	-16%

Operating Expenses

General and Administrative Expenses

General and administrative expenses consist mostly of compensation and related costs for personnel and facilities, stock-based compensation, finance, human resources, information technology, and fees for consulting and other professional services. Professional services are principally comprised of legal, audit, strategic advisory services, and outsourcing services.

Total general and administrative expenses increased by approximately \$2.7 million for the nine months ended September 30, 2020, as compared to the nine months ended September 30, 2019. There was an increase in professional fees of approximately \$1.9 million primarily due to legal fees relating to the Framatome arbitration, court filing fees, professional fees and insurance expense, an increase of patent write off of \$0.1 million due to certain patent expiration dates, an increase in total employee compensation and employee benefits of approximately \$1.0 million, which costs included a decrease in management and administrative service fees charged to Enfission of \$0.2 million, an increase in accrued bonuses of \$0.3 million and an increase in employee payroll expenses of \$0.3 million. In addition, there were severance payments made of approximately \$0.2 million, for employee layoffs partially due to the uncertainty of COVID-19 on our future business operations and the cessation of the Enfission joint venture, as discussed above. These increases were offset by a decrease in stock-based compensation of approximately \$0.3 million, due to the decrease in stock option expense for prior stock option awards that have become fully vested in prior reporting periods. Total stock-based compensation included in general and administrative expenses was approximately \$0 and \$0.3 million for the nine months ended September 30, 2020 and 2019, respectively.

See Note 7, Stockholders' Equity and Stock-Based Compensation of the Notes to our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for more information regarding our stock-based compensation.

Research and Development

Research and development expenses in 2020 and 2019 consist primarily of employee compensation and related fringe benefits including stock-based compensation, and consulting fees, including work performed and billed to our Enfission joint venture in 2019.

Total research and development expenses decreased by approximately \$1.4 million for the nine months ended September 30, 2020, as compared to the nine months ended September 30, 2019, due to the transitioning from work relating to Enfission to developing a new fuel development strategy with U.S. Department of Energy national laboratories. There was a decrease in employee compensation and employee benefits working on research projects of approximately \$0.7 million, which costs included a decrease in allocated accrued bonuses and payroll expenses of approximately \$0.9 million, offset by a decrease in management and administrative service fees charged to Enfission of approximately \$0.2 million. In addition, there was a decrease in professional fees of approximately \$0.2 million, decrease in consulting fees of approximately \$0.2 million, and a decrease in stock-based compensation of approximately \$0.3 million, due to the decrease in stock option expense for prior stock option awards that had vested. Total stock-based compensation included in research and development expenses was approximately \$0 and \$0.3 million for the nine months ended September 30, 2020 and 2019, respectively.

Due to the nature of our research and development expenditures, cost and schedule estimates are inherently uncertain and can vary significantly as new information and the outcome of these research and development activities become available. For 2020, we anticipate a significant decrease in research and development expense compared to 2019, partially due to the uncertainty of COVID-19 on our future business operations, resulting in budgetary constraints due primarily to current market conditions and the uncertainty of future liquidity and capital resources available to us to conduct our future research and development activities.

Other Operating Income and (Loss)

Reported in other operating income and (loss) is other income for activities performed by our employees and consultants billed to the Enfission joint venture for research and development work and our share of the allocated loss in Enfission. Enfission was inactive at September 30, 2020 and December 31, 2019 and no consulting services were performed on behalf of Enfission for the nine months ended September 30, 2020. Therefore, no amounts related to the equity method investment in Enfission have been recorded on the condensed consolidated statements of operations for the nine months ending September 30, 2020. As such, total other operating (loss) decreased by approximately \$2.9 million for the nine months ended September 30, 2020, as compared to the nine months ended September 30, 2019.

Other income from the Enfission joint venture decreased by approximately \$0.9 million for the nine months ended September 30, 2020 as compared to the nine months ended 2019. Equity in loss from the Enfission joint venture decreased by approximately \$3.8 million for the nine months ended September 30, 2020 as compared to the nine months ended 2019, which consisted of our share of the allocated loss in Enfission in 2019.

During the nine months ended September 30, 2020, the Company did not provide additional equity contributions or share any loss in Enfission. The Company had not separately guaranteed any obligations of Enfission at September 30, 2020 and December 31, 2019 and does not believe that it is obligated under the joint venture operating agreement to fund its deficit capital account balance in Enfission to pay for any liabilities incurred by Enfission and therefore did not record its share of losses in Enfission at September 30, 2020 and December 31, 2019.

There was an increase in grant income of approximately \$30,000 for the nine ended September 30, 2020 with a charge to research and development expenses and a corresponding amount to other income. There was no grant income in 2019.

Other Income

There was a net decrease in other income of approximately \$0.2 million due to a decrease in interest income generated from the interest earned from the purchase of treasury bills and from our bank savings account for the nine months ended September 30, 2020, as compared to the nine months ended September 30, 2019.

Provision for Income Taxes

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company is currently evaluating the impact of the CARES Act, but at present does not expect that the NOL carryback provision of the CARES Act would result in a material cash benefit to us. We incurred a pre-tax net loss for both 2020 and 2019. We reviewed all sources of income for purposes of recognizing the deferred tax assets and concluded a full valuation allowance for 2020 and 2019 was necessary. Therefore, we did not have a provision for taxes for the nine months ended September 30, 2020 and 2019.

LIQUIDITY, CAPITAL RESOURCES AND FINANCIAL POSITION

Liquidity outlook

We believe we will have adequate liquidity over the next 12 months to operate our business and meet our current cash requirements. We reduced our 2020 and 2021 operating budgets for discretionary spending, other than for legal expenses, including revising our research and development strategy to reduce current R&D costs and reduced payroll and payroll related benefit costs through employee layoffs, the transition of our Executive Chairman of the Board of Directors to a non-executive role, and the conversion of some employees to consultants. While the impact and duration of COVID-19 on our business activities in the future is currently uncertain, the situation required us to reduce our operating budgets.

[Table of Contents](#)

At September 30, 2020, we had cash and cash equivalents of approximately \$17.4 million, as compared to approximately \$18.0 million at December 31, 2019, a decrease of approximately \$0.6 million. A cash inflow of approximately \$5.1 million resulted from net proceeds from the sale of approximately 1.1 million shares of common stock during the nine months ended September 30, 2020. This cash inflow was offset by net cash used in operating activities of approximately \$5.6 million and \$0.1 million in investing activities associated with incurring patent legal and filing costs.

We currently project a negative cash flow from operations averaging approximately \$1.0 million per month for our general and administrative and research and development expenses, for total expected expenditures of approximately \$12 million for the next 12 months. We believe that our cash at September 30, 2020 exceeds our revised budgeted expenditures through the third quarter of 2021. However, there are inherent uncertainties in forecasting future expenditures, especially forecasting for a significantly revised level of operations and with uncertainties such as to how COVID-19 may affect costs and operations. Accordingly, the potential for budget variances in the projection of the Company's planned operations, plus any additional expenditures that may result from unexpected developments, such as additional expenditures that might result from additional legal costs and unexpected fees relating to our arbitration matter. Taking into account these above uncertainties, it raises substantial doubt about the Company's ability to continue as a going concern for the 12 months following the date of this filing.

We can provide no assurances about meeting our budgeted expenditures regarding our future research and development efforts beyond the next 12 months, as well as predicting future market trends in nuclear power that can affect the future sale of our nuclear fuel. Furthermore, any negative results from our research and development may require us to increase our research and development spending to achieve our desired milestones in developing our nuclear fuel. There can be no assurance that the Enfission arbitration will not affect our ability to continue to advance our research and development efforts. These additional capital needs relate to the development, manufacturing, and commercialization of our nuclear fuel assemblies. We have the ability to delay or reduce incurring certain operating expenses, including research and development expenses, in the next 12 to 15 months, which could reduce our cash flow shortfall, if needed.

The current primary sources of cash available to us for the next 12 months are potential funding from equity investments, including our ATM financing arrangement. The Company has an effective shelf registration statement on Form S-3 (File No. 333-223674) filed on March 15, 2018 and declared effective March 23, 2018 that will expire on March 23, 2021. Due to the offering limitations currently applicable under General Instruction I.B.6. of Form S-3 and the market valuation of our current public float, we may be limited on the amount of funding available under our existing shelf registration statement or a new shelf registration statement. We have no debt or debt credit lines and we have financed our operations to date through our prior years' consulting revenue margins and the sale of our preferred stock and common stock. Management believes that public or private equity investments will be available in the future, however adverse market conditions in our common stock price and trading volume, as well as other factors like COVID-19 could substantially impair our ability to raise capital in the future. On October 9, 2020, we updated the aggregate amount that may be issued and sold under the 2019 ATM from \$13.5 million to \$14.7 million by filing a prospectus supplement pursuant to which we registered an additional \$1.1 million of shares of common stock. As of the date of this filing, we have approximately \$2.6 million of shares of common stock available to be sold under the 2019 ATM.

Short-Term and Long-Term Liquidity Sources

As discussed above, we may seek new financing bringing us additional sources of capital, depending on the capital market conditions of our common stock, over the next 12 months. There can be no assurance that these additional sources of capital will be made available to us. The primary potential sources of cash that may be available to us are as follows:

- Equity or debt investment from third party investors in Lightbridge; and
- Strategic investment to support the remaining research and development activities required to further enhance and complete the development of our fuel products to a commercial stage.

In support of our long-term business with respect to our fuel technology business, we endeavour to create strategic alliances with other parties during the next three years, to support the remaining research and development activities that is required to further enhance and complete the development of our fuel products to a commercial stage. We may be unable to form such strategic alliances on terms acceptable to us or at all.

See Note 7, Stockholders' Equity and Stock-Based Compensation, of the Notes to our unaudited condensed consolidated financial statements included in Part I, Item 1, Financial Statements, of this this Quarterly Report on Form 10-Q for information regarding our prior financings.

Off Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity or capital expenditures or capital resources that is material to an investor in our securities.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Required.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company's management, the Company's principal executive officer and principal financial officer have concluded that the Company's disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were effective as of September 30, 2020 to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company's internal control over financial reporting during the third quarter of 2020 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. For a description of legal proceedings involving the Company, see the information set forth below and under Litigation in Note 5, Commitments and Contingencies of the Notes to our condensed consolidated financial statements in Part I. Item 1. *Financial Statements and Supplementary Data*, of this Quarterly Report on Form 10-Q.

Filing of Arbitration

On February 7, 2020, we filed a request for arbitration (the “Arbitration Request”) in the International Court of Arbitration of the International Chamber of Commerce against Framatome, seeking to obtain, inter alia, a declaration that the R&D Services Agreement, dated November 14, 2017, by and among Framatome, Enfission, and the Company (as amended by Amendment Number One, dated January 25, 2018, and Amendment Number Two, dated June 20, 2018, the “RDSA”) was validly terminated and is no longer in force, and to obtain compensation for the damages incurred.

On April 3, 2020, Framatome submitted its answer to the Arbitration Request, disputing the Company’s claims, setting out its own counterclaims against the Company and its request for relief sought from the International Court of Arbitration. The Company believes it has meritorious claims in the arbitration and intends to pursue its interests vigorously.

ITEM 1A. RISK FACTORS

COVID-19 OUTBREAK COULD ADVERSELY AFFECT OUR BUSINESS

The recent outbreak of COVID-19 in the United States and globally has resulted in the United States and other countries halting or sharply curtailing the movement of people, goods and services. All of this has caused extended shutdowns of businesses and the prolonged economic impact remains uncertain. At this point, we have experienced and may continue to experience a reduction of our research and development expenses and an increase in our general and administrative expenses. Other than such changes, we believe the conditions will have not a material adverse effect on our business, but given the rapidly changing developments we cannot accurately predict what effects these conditions will have on our financial position, results of operations and liquidity, including our research and development activities, which will depend on, among other factors, the ultimate geographic spread of the virus, the duration of the outbreak and travel restrictions and business closures imposed by the United States and various other governments. The coronavirus may have a material adverse effect on our ability to obtain financing, which is needed to generate sufficient cash flows to conduct our businesses activities in the future.

There have been no other material changes to our risk factors from the risk factors previously disclosed in the 2019 Annual Report.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES OR USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not Applicable

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

EXHIBIT INDEX –

Exhibit Number	Description
10.1	Lightbridge Corporation 2020 Omnibus Incentive Plan (incorporated by reference to Appendix A to the definitive proxy statement filed on July 27, 2020).
31.1	Rule 13a-14(a)/15d-14(a) Certification - Principal Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) Certification - Principal Financial Accounting Officer
32	Section 1350 Certifications
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LIGHTBRIDGE CORPORATION

Date: November 5, 2020

By: /s/ Seth Grae

Name: Seth Grae

Title: President, Chief Executive Officer and
Director
(Principal Executive Officer)

By: /s/ Larry Goldman

Name: Larry Goldman

Title: Chief Financial Officer
(Principal Financial Officer and Principal
Accounting Officer)

Certification of Principal Executive Officer

I, Seth Grae, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Lightbridge Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2020

By: /s/ Seth Grae

Seth Grae
Principal Executive Officer

Certification of Principal Financial Officer

I, Larry Goldman, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Lightbridge Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2020

By: /s/ Larry Goldman

Larry Goldman
Chief Financial Officer
(Principal Financial and Principal Accounting
Officer)

Section 1350 Certifications

STATEMENT FURNISHED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, the Chief Executive Officer and Chief Financial Officer of Lightbridge Corporation, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge on the date hereof:

1. the Quarterly Report on Form 10-Q of Lightbridge Corporation for the quarter ended September 30, 2020, filed on the date hereof with the Securities and Exchange Commission (the Report), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Lightbridge Corporation.

Date: November 5, 2020

By: /s/ Seth Grae
Name: Seth Grae
Title: President, Chief Executive Officer and Director
(Principal Executive Officer)

By: /s/ Larry Goldman
Name: Larry Goldman
Title: Chief Financial Officer
(Principal Financial Officer and Principal
Accounting Officer)